



Council

David R. Sibley

President
Bethesda, Maryland

John D. Schuetz

President-Elect
St. Jude Children's Research Hospital

Kenneth E. Thummel

Past President
University of Washington

Charles P. France

Secretary/Treasurer
The University of Texas Health
Science Center at San Antonio

John J. Tesmer

Secretary/Treasurer-Elect
University of Michigan

Dennis C. Marshall

Past Secretary/Treasurer
Ferring Pharmaceuticals, Inc.

Margaret E. Gnegy

Councilor
University of Michigan Medical School

Wayne L. Backes

Councilor
Louisiana State University Health
Sciences Center

Carol L. Beck

Councilor
Thomas Jefferson University

Mary E. Vore

Chair, Board of Publications Trustees
University of Kentucky

Brian M. Cox

FASEB Board Representative
Uniformed Services University
of the Health Sciences

Scott A. Waldman

Chair, Program Committee
Thomas Jefferson University

Judith A. Siuciak

Executive Officer

November 8, 2016

Kiran Sapkota
Pharmacology & Experimental Neuroscience Department
University of Nebraska Medical Center
601 S Saddle Creek Road
Omaha, NE 68106

Email: knsapkota11@gmail.com

Dear Kiran Sapkota:

This is to grant you permission to include the following article in your thesis entitled "Target Validation and Pharmacological Characterization of Novel NMDAR Modulators" for the University of Nebraska Medical Center:

Kiran Sapkota, Zhihao Mao, Paul Synowicki, Dillon Lieber, Meng Liu, Tsuneya Ikezu, Vivek Gautam, and Daniel T. Monaghan, GluN2D N-Methyl-D-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia, *J Pharmacol Exp Ther* 2016, 356(3):702-711,
DOI: <http://dx.doi.org/10.1124/jpet.115.230391>

On the first page of each copy of this article, please add the following:

Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics. All rights reserved.

In addition, the original copyright line published with the paper must be shown on the copies included with your thesis.

Sincerely yours,

Richard Dodenhoff
Journals Director